SOGUG - Spanish Oncology Genitourinary Group published results from a clinical trial comparing olaparib plus abiraterona to placebo plus abiraterona in patients with mCRPC 1st line and mutations in a single gene, showing a 0.66 HR for overall survival in the global population with a 7.4 month improvement over placebo plus abiraterona.

SOGUG is a non-profit association established in 1998, created due to the concern of a group of national oncologists specialised in the treatment of genitourinary tumours, including prostate, kidney and bladder. Our MISSION is to research and help patients suffering from prostate, kidney or bladder cancer through the development of specific programmes aimed at the study and research of urological tumours and to standardize treatments in this area of oncology in Spain. Our OBJECTIVES are: - Research - Help and Improve the qualitiy of life of patients suffering from Prostate, Kidney or Bladder Cancer through the development of Clinical Trials and Research Projects - Publish and disseminate latest advances in Genitourinary Tumors - Inform patients about their pathology - Collaborate with other national and international research groups.